Результаты поиска

Unraveling the Role of Allo-Antibodies and Transplant Injury.

Alloimmunity driving rejection in the context of solid organ transplantation can be grossly divided into mechanisms predominantly driven by either T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR), though the co-existence of both types of rejections can be seen in a variable number of sampled grafts. Acute TCMR can generally be well controlled by the establishment of effective immunosuppression (1, 2). Acute ABMR is a low frequency finding in the current era of blood group and HLA donor/recipient matching and the avoidance of engraftment in the context of high-titer, pref

Совпадение в полном тексте источника
… glomerulopathy | ( 79 , 208 ) Anti-PRKRIP1ab | Kidney | Cronic kidney disease | ( 32 , 208 ) Antivimentin ab | Heart | It did not correlate with early post-transplant rejection or graft survival | ( 32 ) Non-HLA pigmy ab | Heart | Mortality | ( 209 ) Antibodies against | Kidney | Acute ABMR | ( 210 ) Endoglin …

Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications.

The most important limitations of chemotherapeutic agents are severe side effects and the development of multi-drug resistance. Recently, the clinical successes achieved with immunotherapy have revolutionized the treatment of several advanced-stage malignancies, but most patients do not respond and many of them develop immune-related adverse events. Loading synergistic combinations of different anti-tumor drugs in nanocarriers may enhance their efficacy and reduce life-threatening toxicities. Thereafter, nanomedicines may synergize with pharmacological, immunological, and physical combined tre

Совпадение в полном тексте источника
… In this work, an 8 nm iron oxide core was coated with negatively charged silica-polyethylene glycol (PEG) and subsequently conjugated with a peptide targeting tumor vessels (endoglin-binding peptide), a chemotherapeutic drug (doxorubicin), and an immunomodulating agent (Poly IC). …

Lipocalin 2-not only a biomarker: a study of current literature and systematic findings of ongoing clinical trials.

Lipocalin 2 (Lcn2), also known as neutrophil gelatinase-associated lipocalin, is an innate immune protein encoded by the LCN2 gene. In this study, we investigated various roles and functions of Lcn2 characterized in a systems-based format and evaluated its therapeutic potentials and clinical relevance for diagnosis and prognosis. An additional systematic presentation was presented for 70 ongoing clinical trials utilizing Lcn2 in the diagnostic and prognostic setting as a key outcome measure. With trials being conducted through December 2030, Lcn2 will become all the more relevant given its ass

Совпадение в полном тексте источника
… tyrosine kinase (sFlt-1) between 26 and 34 weeks of pregnancy; change in circulating placental growth factor (PIGF) between 26 and 34 weeks of pregnancy; change in circulating levels of vascular endothelial growth factors (VEGF) between 26 and 34 weeks of pregnancy; change in circulating levels of soluble endogline …

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.

Transforming growth factor-beta (TGF-β) signaling regulates a wide range of biological processes. TGF-β plays an important role in tumorigenesis and contributes to the hallmarks of cancer, including tumor proliferation, invasion and metastasis, inflammation, angiogenesis, and escape of immune surveillance. There are several pharmacological approaches to block TGF-β signaling, such as monoclonal antibodies, vaccines, antisense oligonucleotides, and small molecule inhibitors. Galunisertib (LY2157299 monohydrate) is an oral small molecule inhibitor of the TGF-β receptor I kinase that specifically

Совпадение в полном тексте источника
… One example is the TGF-βRIII, to which the glycoprotein endoglin (CD105) can bind with high affinity. 9 Figure 2 TGF-βRI (ALK5) and TGF-βRII canonical activation. Note: Galunisertib blocks the kinase of the ALK5 pathway reducing the pSMAD2 activation in cells. …

Mesenchymal Stromal Cells in Neuroblastoma: Exploring Crosstalk and Therapeutic Implications.

Neuroblastoma (NB) is the second most common solid cancer in childhood, accounting for 15% of cancer-related deaths in children. In high-risk NB patients, the majority suffers from metastasis. Despite intensive multimodal treatment, long-term survival remains <40%. The bone marrow (BM) is among the most common sites of distant metastasis in patients with high-risk NB. In this environment, small populations of tumor cells can persist after treatment (minimal residual disease) and induce relapse. Therapy resistance of these residual tumor cells in BM remains a major obstacle for the cure of NB.

Совпадение в полном тексте источника
… Addition of an anti-CD105 (Endoglin) antibody restored the efficiency of the aNKC/dinutuximab treatment. Since the anti-CD105 antibody eliminates not only MSCs but also monocytes and endothelial cells, the protective effect cannot be attributed solely to MSCs here. …

A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments.

Tumors are composed of a plethora of extracellular matrix, tumor and non-tumor cells that form a tumor microenvironment (TME) that nurtures the tumor cells and creates a favorable environment where tumor cells grow and proliferate. In multiple myeloma (MM), the TME is the bone marrow (BM). Non-tumor cells can belong either to the non-hematological compartment that secretes soluble mediators to create a favorable environment for MM cells to grow, or to the immune cell compartment that perform an anti-MM activity in healthy conditions. Indeed, marrow-infiltrating lymphocytes (MILs) are associate

Совпадение в полном тексте источника
… Moreover, endothelial cells in the BM of MM modify their phenotype, expressing surface receptors related to angiogenesis, such as VEGFR-2 and Tie2/Tek, and increased expression of the β3-integrin and endoglin [ 83 ]. …

Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients.

The development of a wide range of novel antineoplastic therapies has improved the prognosis for patients with a wide range of malignancies, which has increased the number of cancer survivors substantially. Despite the oncological benefit, cancer survivors are exposed to short- and long-term adverse cardiovascular toxicities associated with anticancer therapies. Systemic hypertension, the most common comorbidity among cancer patients, is a major contributor to the increased risk for developing these adverse cardiovascular events. Cancer and hypertension have common risk factors, have overlappi

Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment.

The concept of cancer as a systemic disease, and the therapeutic implications of this, has gained special relevance. This concept encompasses the interactions between tumor and stromal cells and their microenvironment in the complex setting of primary tumors and metastases. These factors determine cellular co-evolution in time and space, contribute to tumor progression, and could counteract therapeutic effects. Additionally, cancer therapies can induce cellular and molecular responses in the tumor and host that allow them to escape therapy and promote tumor progression. In this study, we descr

Novel Investigations of Flavonoids as Chemopreventive Agents for Hepatocellular Carcinoma.

We would like to highlight the application of natural products to hepatocellular carcinoma (HCC). We will focus on the natural products known as flavonoids, which target this disease at different stages of hepatocarcinogenesis. In spite of the use of chemotherapy and radiotherapy in treating HCC, patients with HCC still face poor prognosis because of the nature of multidrug resistance and toxicity derived from chemotherapy and radiotherapy. Flavonoids can be found in many vegetables, fruits, and herbal medicines that exert their different anticancer effects via different intracellular signalin

RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic CD5+/CD19+ B lymphocytes in the blood. These cells migrate to and proliferate in the bone marrow and lymphoid tissues. Despite the development of new therapies for CLL, drug resistance and disease relapse still occur; novel treatment approaches are therefore still needed. Inhibition of the angiogenesis involved in the progression of CLL might be a relevant therapeutic strategy. The literature data indicate that vascular endothelial growth factor, angiopoietin-2, and matrix metalloproteinase-9 are pro-angiogen

Совпадение в полном тексте источника
… Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia Neoplasma 2014 61 585 592 10.4149/neo_2014_071 25030442 86. Lewis R. Maurer H.C. Singh N. Gonzalez-Menendez I. Wirth M. Schick M. Zhang L. Isaakidis K. Scherger A.K. …

ISEV2018 абстрактная книга

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Passive Monoclonal and Polyclonal Antibody Therapies

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… results Angiosarcoma phase III 2019 TAPPAS trial Prostate ca phase II 2021 NSCLC phase I 2019 Intravenous Endoglin (CD105) Catumaxomab Removab FDA approved pend 2017) EU approved 2009 Removab: A trifunctional rat/murine hybrid antibody IgG2a/IgG2b Antineoplastic Removab Ovarian cancer phase II, malignant …

Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials.

A key issue with modern cancer treatments is the emergence of resistance to conventional chemotherapy and molecularly targeted medicines. Cancer nanotherapeutics were created in order to overcome the inherent limitations of traditional chemotherapeutics. Over the last few decades, cancer nanotherapeutics provided unparalleled opportunities to understand and overcome drug resistance through clinical assessment of rationally designed nanoparticulate delivery systems. In this context, various design strategies such as passive targeting, active targeting, nano-drug, and multimodal nano-drug combin

Use of Cannabis and Cannabinoids for Treatment of Cancer.

The endocannabinoid system (ECS) is an ancient homeostasis mechanism operating from embryonic stages to adulthood. It controls the growth and development of many cells and cell lineages. Dysregulation of the components of the ECS may result in uncontrolled proliferation, adhesion, invasion, inhibition of apoptosis and increased vascularization, leading to the development of various malignancies. Cancer is the disease of uncontrolled cell division. In this review, we will discuss whether the changes to the ECS are a cause or a consequence of malignization and whether different tissues react dif

Natural anti-cancer products: insights from herbal medicine.

Herbal medicine exhibits a broad spectrum of potent anti-cancer properties, including the enhancement of tumor immune responses, reversal of multidrug resistance, regulation of autophagy and ferroptosis, as well as anti-proliferative, pro-apoptotic, and anti-metastatic effects. This review systematically explores recent advances (primarily documented since 2019) in research on key anti-cancer compounds derived from herbal medicine, such as apigenin, artemisinin, berberine, curcumin, emodin, epigallocatechin gallate (EGCG), ginsenosides, icariin, resveratrol, silibinin, triptolide, and ursolic

UMIB Summit 2015

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstract

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

ISEV2020 Резюме

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Четвертое Международное совещание ИСЕВ, ISEV2015.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.